Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8974443 | 0.82 | SCN9A (0.39) | GRIN2BTSHRSCN9AHTR2AHTR2C | |
| SCHEMBL28195182 | 0.78 | HTR1A (0.47) | HTR2AHTR2CHTR2B | |
| SCHEMBL27845790 | 0.78 | TSHR (0.44) | TSHRHTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL28170631 | 0.76 | HCRTR1 (0.43) | BACE1GRIN2BHCRTR1HCRTR2SCN9A | |
| SCHEMBL21050038 | 0.76 | GRIN2B (0.40) | GRIN2BHCRTR1HCRTR2SCN9AHTR2A | |
| SCHEMBL29474981 | 0.75 | HTR2C (0.50) | TSHRHTR2AHTR2CHTR2BL3MBTL1 | |
| SCHEMBL935859 | 0.75 | HTR2C (0.50) | TSHRHTR2AHTR2CHTR2BL3MBTL1 | |
| SCHEMBL6484237 | 0.75 | HTR2C (0.50) | TSHRHTR2AHTR2CHTR2BL3MBTL1 | |
| SCHEMBL12473637 | 0.74 | PROKR1 (0.45) | GRIN2BHCRTR1HCRTR2HTR2CDDB1 | |
| SCHEMBL29750491 | 0.74 | ADRA1A (0.47) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| EP-1904451-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006136830-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| EP-1673463-A1 | METHOD FOR TRANSFORMING EPOXY CARRIER OF TRIFLUOROMETHYL GROUPS | Rhodia Chimie (FR) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005038036-A1 | METHOD FOR TRANSFORMING EPOXY CARRIER OF TRIFLUOROMETHYL GROUPS | RHODIA CHIMIE (FR) | 2005-04-28 | — | — | WO | disclosed |
| EP-0799231-B1 | SPIROKETAL DERIVATIVES, COMPOSITIONS CONTAINING THEM AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME (GB) | 1999-03-17 | — | — | EP | disclosed |
| US-5728695-A | TACHYKININ ANTAGONISTS USEFUL IN TREATMENT OR PREVENTION OF PAIN, INFLAMMATION, MIGRAINE, EMESIS AND POSTHERPETIC NEURALGIA | MERCK SHARP & DOHME LIMITED (GB) | 1998-03-17 | — | — | US | disclosed |
| WO-1996020197-A1 | SPIROKETAL DERIVATIVES, COMPOSITIONS CONTAINING THEM AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-07-04 | — | — | WO | disclosed |
| US-5225602-A | Catalytic rearrangement of phenyl-substituted epoxide | BASF AKTIENGESELLSCHAFT (DE) | 1993-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ERBB2, ABL1, GRK2 | BACE1 3530/4885GRIN2B 907/4885HCRTR1 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.